Acurx Pharmaceuticals Reports $1.99 Million Net Loss in Q3 2025, Down 29% Year-Over-Year

Acurx Pharmaceuticals, Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $1.99 million, a 29% decrease from the $2.82 million loss recorded in the same period last year. For the nine months ending September 30, 2025, the company reported a net loss of $6.39 million, down 44% from $11.32 million in the prior year. The reduction in losses is attributed to a significant decrease in research and development expenses, which fell to $429,691 for the quarter and $1.55 million for the nine months, compared to $1.20 million and $4.58 million, respectively, in 2024. General and administrative expenses remained relatively stable, totaling $1.60 million for the quarter and $4.92 million for the nine months.

The company’s total operating expenses for the third quarter were $2.03 million, a 28% decrease from $2.83 million in the prior year. This decline was primarily driven by reduced research and development costs, which were lower due to decreased manufacturing and consulting fees associated with prior Phase 2b and Phase 3 preparations. Acurx's interest income also saw a notable increase, rising to $35,911 in the third quarter from $5,001 a year earlier, contributing to the overall reduction in net loss.

In terms of strategic developments, Acurx has made significant organizational changes, including a 1-for-20 reverse stock split executed on August 4, 2025, which helped the company regain compliance with Nasdaq's minimum bid price requirement. Additionally, the company increased its authorized shares from 200 million to 250 million, a move approved by shareholders on September 16, 2025. Acurx has also entered into an equity line of credit purchase agreement with Lincoln Park Capital Fund, allowing for the potential sale of up to $12 million in shares, with approximately $2.4 million raised under this agreement as of September 30, 2025.

As of the end of the reporting period, Acurx had cash and cash equivalents of approximately $5.91 million, an increase from $3.71 million at the end of 2024. The company reported working capital of $3.64 million, which it believes will not be sufficient to meet its anticipated cash requirements for at least the next 12 months. Acurx continues to explore additional financing options to support its operations and product development, particularly for its lead antibiotic candidate, ibezapolstat, which is in late-stage clinical trials targeting Clostridioides difficile infections.

Looking ahead, Acurx anticipates ongoing losses as it continues to invest in research and development activities. The company remains focused on advancing its clinical trials and exploring strategic partnerships for commercialization. However, it acknowledges the inherent uncertainties in the biopharmaceutical industry, including regulatory approvals and market conditions, which could impact its future financial performance and operational capabilities.